FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938450158> ?p ?o ?g. }

• W2938450158 endingPage "323" @default.
• W2938450158 startingPage "315" @default.
• W2938450158 abstract "Approximately 1-2% of patients with non‒small-cell lung cancer (NSCLC) harbor ROS1 rearrangements. Crizotinib, an oral small-molecule tyrosine kinase inhibitor (TKI) that targets anaplastic lymphoma kinase (ALK), MET, and ROS1, has shown marked antitumor activity in patients with ROS1-positive advanced NSCLC.Our objective was to analyze the efficacy and safety of crizotinib treatment in Chinese patients with advanced NSCLC with ROS1 rearrangement in real-world clinical practice.We included 35 patients with ROS1-positive NSCLC in this retrospective analysis. All received crizotinib 250 mg twice daily between March 2016 and April 2018 at the Fudan University Shanghai Cancer Center. All had histologically or cytologically confirmed locally advanced or metastatic NSCLC with ROS1 rearrangements, which were identified by fluorescence in situ hybridization, reverse transcriptase polymerase chain reaction, or next-generation sequencing. The main outcome measures were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events.The median age of the patients was 51.0 years; 23 (65.7%) were female and 28 (80.0%) were never smokers. All were diagnosed as having adenocarcinoma; eight patients (22.9%) had brain metastases at baseline. The ORR and DCR were 71.4% and 94.3%, respectively. The estimated median PFS was 11.0 months (95% confidence interval [CI] 7.8-14.2). The estimated median OS was 41.0 months (95% CI 22.5-59.5). Elevated transaminases (54.3%), vision disorder (25.7%), elevated blood creatinine (22.9%), diarrhea (20.0%), and vomiting (20.0%) were the most commonly reported adverse effects.Crizotinib was effective and well tolerated in Chinese patients with ROS1-positive advanced NSCLC in real-world clinical practice. The progression sites and patterns, as well as treatments after first disease progression on crizotinib were diverse. Crizotinib beyond progressive disease and local therapy after failure of crizotinib treatment were feasible and effective in clinical practice." @default.
• W2938450158 created "2019-04-25" @default.
• W2938450158 creator A5001959086 @default.
• W2938450158 creator A5004341112 @default.
• W2938450158 creator A5008100904 @default.
• W2938450158 creator A5014314263 @default.
• W2938450158 creator A5057243097 @default.
• W2938450158 creator A5065195779 @default.
• W2938450158 creator A5065503019 @default.
• W2938450158 creator A5065930824 @default.
• W2938450158 creator A5068735198 @default.
• W2938450158 creator A5073681238 @default.
• W2938450158 creator A5089564069 @default.
• W2938450158 date "2019-04-11" @default.
• W2938450158 modified "2023-10-18" @default.
• W2938450158 title "Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice" @default.
• W2938450158 cites W1986115078 @default.
• W2938450158 cites W1990626198 @default.
• W2938450158 cites W1994539763 @default.
• W2938450158 cites W2043516790 @default.
• W2938450158 cites W2050249255 @default.
• W2938450158 cites W2099530756 @default.
• W2938450158 cites W2103447891 @default.
• W2938450158 cites W2111724182 @default.
• W2938450158 cites W2119317963 @default.
• W2938450158 cites W2130488043 @default.
• W2938450158 cites W2134787029 @default.
• W2938450158 cites W2168691181 @default.
• W2938450158 cites W2218718059 @default.
• W2938450158 cites W2228467092 @default.
• W2938450158 cites W2588717112 @default.
• W2938450158 cites W2592512313 @default.
• W2938450158 cites W2602478132 @default.
• W2938450158 cites W2772410896 @default.
• W2938450158 cites W2794491531 @default.
• W2938450158 cites W2800286167 @default.
• W2938450158 doi "https://doi.org/10.1007/s11523-019-00636-6" @default.
• W2938450158 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6602983" @default.
• W2938450158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30976989" @default.
• W2938450158 hasPublicationYear "2019" @default.
• W2938450158 type Work @default.
• W2938450158 sameAs 2938450158 @default.
• W2938450158 citedByCount "22" @default.
• W2938450158 countsByYear W29384501582019 @default.
• W2938450158 countsByYear W29384501582020 @default.
• W2938450158 countsByYear W29384501582021 @default.
• W2938450158 countsByYear W29384501582022 @default.
• W2938450158 countsByYear W29384501582023 @default.
• W2938450158 crossrefType "journal-article" @default.
• W2938450158 hasAuthorship W2938450158A5001959086 @default.
• W2938450158 hasAuthorship W2938450158A5004341112 @default.
• W2938450158 hasAuthorship W2938450158A5008100904 @default.
• W2938450158 hasAuthorship W2938450158A5014314263 @default.
• W2938450158 hasAuthorship W2938450158A5057243097 @default.
• W2938450158 hasAuthorship W2938450158A5065195779 @default.
• W2938450158 hasAuthorship W2938450158A5065503019 @default.
• W2938450158 hasAuthorship W2938450158A5065930824 @default.
• W2938450158 hasAuthorship W2938450158A5068735198 @default.
• W2938450158 hasAuthorship W2938450158A5073681238 @default.
• W2938450158 hasAuthorship W2938450158A5089564069 @default.
• W2938450158 hasBestOaLocation W29384501581 @default.
• W2938450158 hasConcept C117643217 @default.
• W2938450158 hasConcept C121608353 @default.
• W2938450158 hasConcept C126322002 @default.
• W2938450158 hasConcept C143998085 @default.
• W2938450158 hasConcept C197934379 @default.
• W2938450158 hasConcept C2775999482 @default.
• W2938450158 hasConcept C2776232967 @default.
• W2938450158 hasConcept C2776256026 @default.
• W2938450158 hasConcept C2778347629 @default.
• W2938450158 hasConcept C2779422266 @default.
• W2938450158 hasConcept C2781182431 @default.
• W2938450158 hasConcept C71924100 @default.
• W2938450158 hasConcept C90924648 @default.
• W2938450158 hasConceptScore W2938450158C117643217 @default.
• W2938450158 hasConceptScore W2938450158C121608353 @default.
• W2938450158 hasConceptScore W2938450158C126322002 @default.
• W2938450158 hasConceptScore W2938450158C143998085 @default.
• W2938450158 hasConceptScore W2938450158C197934379 @default.
• W2938450158 hasConceptScore W2938450158C2775999482 @default.
• W2938450158 hasConceptScore W2938450158C2776232967 @default.
• W2938450158 hasConceptScore W2938450158C2776256026 @default.
• W2938450158 hasConceptScore W2938450158C2778347629 @default.
• W2938450158 hasConceptScore W2938450158C2779422266 @default.
• W2938450158 hasConceptScore W2938450158C2781182431 @default.
• W2938450158 hasConceptScore W2938450158C71924100 @default.
• W2938450158 hasConceptScore W2938450158C90924648 @default.
• W2938450158 hasIssue "3" @default.
• W2938450158 hasLocation W29384501581 @default.
• W2938450158 hasLocation W29384501582 @default.
• W2938450158 hasLocation W29384501583 @default.
• W2938450158 hasLocation W29384501584 @default.
• W2938450158 hasOpenAccess W2938450158 @default.
• W2938450158 hasPrimaryLocation W29384501581 @default.
• W2938450158 hasRelatedWork W1974903221 @default.
• W2938450158 hasRelatedWork W2057269827 @default.
• W2938450158 hasRelatedWork W2156486640 @default.
• W2938450158 hasRelatedWork W2162074187 @default.

• next